Get the Stockscreener App
7.37
8.22%
0.56
After Hours:
7.37
Profound Medical Corp stock is traded at $7.37, with a volume of 294.60K.
It is up +8.22% in the last 24 hours and up +10.66% over the past month.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
See More
Previous Close:
$6.81
Open:
$6.88
24h Volume:
294.60K
Relative Volume:
3.79
Market Cap:
$267.81M
Revenue:
$18.81M
Net Income/Loss:
$-38.90M
P/E Ratio:
-5.9073
EPS:
-1.2476
Net Cash Flow:
$-38.83M
1W Performance:
+11.84%
1M Performance:
+10.66%
6M Performance:
-4.66%
1Y Performance:
+23.35%
1-Day Range:
$6.80
$7.41
1-Week Range:
$6.54
$7.41
52-Week Range:
$3.76
$8.95
Profound Medical Corp Stock (PROF) Company Profile
Name
Profound Medical Corp
Sector
Industry
Phone
647-476-1350
Address
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROF
Profound Medical Corp
|
7.37 | 241.65M | 18.81M | -38.90M | -38.83M | -1.2476 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Profound Medical Corp Stock (PROF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | Lake Street | Buy |
| Jul-16-24 | Upgrade | Stifel | Hold → Buy |
| Nov-28-23 | Initiated | Stifel | Hold |
| Aug-04-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-21-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-15-20 | Initiated | Jefferies | Buy |
View All
Profound Medical Corp Stock (PROF) Latest News
Profound Medical Corp. (PROF) Edges Higher: Testing Key Resistance Near $6.92Long Setup Ideas - dars.gov.et
Why Profound Medical Corp stock is sliding today - Wealth Awesome
PROF Forecast — Price Target — Prediction for 2027 - TradingView
Profound Medical Corp Actuals & Estimates (NASDAQ:PROF) - TradingView
PRN Forecast — Price Target — Prediction for 2027 - TradingView
Grow Funds Small Cap Fund Outperforms Benchmarks in Q1 2026 - HarianBasis.co
Profound Medical Corp. (PROF) Dropped Despite High Potential - Insider Monkey
Profound Medical Corp (PROF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Profound Medical Corp (PROF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Profound Medical Corp (PROF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Why Profound Medical Corp stock is gaining today - Wealth Awesome
Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medi - The National Law Review
Why Profound Medical Corp stock is rising today - Wealth Awesome
Profound Medical Corp (PROF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PROF Q1 2026 Earnings: Narrower-Than-Expected Loss Beats EstimatesTrough Earnings Signal - newsline.com
Profound Medical Corp (PROF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Profound Medical Corp (PROF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Profound Medical Corp (PROF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Profound Medical Corp (PROF) Institutional Confidence - TradingKey
Profound Medical Corp (PROF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(PROF) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Profound Medical Corp. (PROF) Gains 1.89% as Key Levels Come into FocusIsland Reversal - newsline.com
Profound Medical Corp. (PROF) Edges Lower as Stock Tests Key Support LevelsBuyback Factor - newsline.com
Profound Medical Corp. (PROF) Holds Near Support as Volatility Remains LowProfit Surge Picks - newsline.com
PROF Q1 2026 Earnings: Narrower Loss Than Expected, Shares Edge LowerEarnings Weakness Phase - newsline.com
Profound Medical Corp. (PROF) Gains Nearly 4% as Bullish Momentum BuildsSMA Signal - newsline.com
Why Profound Medical Corp stock is tanking today - Wealth Awesome
How (PROF) Movements Inform Risk Allocation Models - Stock Traders Daily
Profound Medical (PROF) Edges Higher Amid Continued Trade Volume and Technical FirmnessTurnaround Stocks - The Legal Advocate
Profound Medical Q1 2026 Earnings: EPS Beats Estimates, Stock DeclinesEarnings Beat Alert - Newser
PROF Q1 2026 Earnings: EPS Surprises to the Upside, Stock Declines 2%Community Pattern Alerts - Newser
Profound Medical (PROF) Hovers Near Support Amid Modest DeclineFactor Momentum - Newser
[EFFECT] Profound Medical Corp. SEC Filing - Stock Titan
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? - Yahoo Finance
Profound Medical Shareholders Back Board, Question Incentive Plan - The Globe and Mail
Telix partners with EDAP, Profound on prostate imaging tech - Investing.com UK
Profound Medical (NASDAQ: PROF) investors back board, auditor and long‑term incentive units - Stock Titan
Telix to Collaborate With EDAP, Profound Medical to Explore PSMA-PET Imaging in Prostate Cancer Therapies - Moomoo
Profound Medical Showcases TULSA-PRO Integration with PSMA PET Imaging for Prostate Cancer at AUA2026 - Minichart
Profound Medical Q1 earnings call highlights - MSN
Telix to Explore PSMA-PET Imaging in Collaborations with EDAP and Profound - Contract Pharma
How Profound Medical Corp. (PROF) Affects Rotational Strategy Timing - Stock Traders Daily
Profound Medical Highlights TULSA Advances at AUA 2026 - TipRanks
Profound Medical (NASDAQ: PROF) to highlight TULSA and PSMA PET integration at AUA2026 - Stock Titan
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 - The Manila Times
Imaging combo to sharpen prostate cancer treatment planning - Stock Titan
Nearly 70% of Profound Medical shares vote to support full board slate - Stock Titan
Profound Medical Annual General and Special Meeting of Shareholders Voting Results - TMX Newsfile
TradingKey - TradingKey
Profound Medical (NASDAQ: PROF) registers 921,428 resale shares - Stock Titan
Profound Medical (PROF) price target decreased by 26.77% to 8.49 - MSN
Profound Medical Corp Stock (PROF) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):